Display options
Share it on

Ann Gastroenterol. 2017;30(2):209-216. doi: 10.20524/aog.2016.0107. Epub 2016 Dec 01.

Serum levels of vascular endothelial growth factor in non-alcoholic fatty liver disease.

Annals of gastroenterology

Maria-Vasiliki Papageorgiou, Emilia Hadziyannis, Dina Tiniakos, Anastasia Georgiou, Aikaterini Margariti, Athanasios Kostas, George V Papatheodoridis

Affiliations

  1. Academic Department of Gastroenterology, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital (Maria-Vasiliki Papageorgiou, Anastasia Georgiou, Athanasios Kostas, George V. Papatheodoridis).
  2. 2nd Academic Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Hippokration General Hospital (Emilia Hadziyannis, Aikaterini Margariti).
  3. Laboratory of Histology & Embryology, Medical School, National and Kapodistrian University of Athens (Dina Tiniakos), Athens, Greece.

PMID: 28243042 PMCID: PMC5320034 DOI: 10.20524/aog.2016.0107

Abstract

BACKGROUND: This study aimed to assess the significance of serum levels of vascular endothelial growth factor (VEGF) in non-alcoholic fatty liver disease (NAFLD).

METHODS: Sixty-seven consecutive NAFLD patients and 47 healthy controls who visited our liver clinics between May 2008 and December 2010 were included. The NAFLD diagnosis required elevated alanine aminotransferase and/or gamma-glutamyl transpeptidase levels, evidence of hepatic steatosis on ultrasound and/or liver histology, and exclusion of other causes of liver injury. Serum VEGF levels were determined by an enzyme immunoassay. Liver biopsy was obtained in 34 NAFLD patients. Histological lesions were scored by a liver histopathologist.

RESULTS: Serum VEGF levels tended to be lower in matched NAFLD patients than in healthy controls (296±146 vs. 365±186 pg/mL, P=0.092); levels in patients with non-alcoholic steatohepatitis (NASH) also tended to be lower than in those with simple fatty liver (FL) (279±149 vs. 359±190 pg/mL, P=0.095); while VEGF levels were significantly lower in NASH patients than in healthy controls (279±149 vs. 365±186 pg/mL, P=0.041). VEGF levels offered poor predictability for the differentiation between NAFLD patients and controls or between NASH and FL patients. However, patients with high VEGF levels (≥300 pg/mL) were significantly more likely to have FL, either in the total NAFLD population (67% vs. 35%, P=0.019) or in the 34 NAFLD patients with liver biopsy (57% vs. 15%, P=0.023), while those with high VEGF levels also had a significantly lower mean fibrosis score (0.7±0.9 vs. 1.6±1.0, P=0.017).

CONCLUSION: Our data suggest that serum VEGF levels are equally high in healthy controls and in patients with simple fatty liver, but tend to decrease when NASH develops.

Keywords: Nonalcoholic fatty liver disease; angiogenesis markers; nonalcoholic steatohepatitis; vascular endothelial growth factor; vascular endothelial growth factor receptors

Conflict of interest statement

Conflict of interest: None

References

  1. Am J Gastroenterol. 1999 Sep;94(9):2467-74 - PubMed
  2. Hepatology. 2011 Sep 2;54(3):1082-90 - PubMed
  3. Aliment Pharmacol Ther. 2005 Jul 1;22(1):23-30 - PubMed
  4. Semin Diagn Pathol. 2005 Nov;22(4):330-8 - PubMed
  5. Hepatology. 2005 Sep;42(3):696-701 - PubMed
  6. Gastroenterology. 2016 Jun;150(8):1769-77 - PubMed
  7. Ann Hepatol. 2007 Jul-Sep;6(3):170-3 - PubMed
  8. Annu Rev Pathol. 2016 May 23;11:451-96 - PubMed
  9. Hepatology. 2004 Aug;40(2):386-93 - PubMed
  10. Hepatol Int. 2013 Mar;7(1):4-12 - PubMed
  11. Hepatology. 2009 Mar;49(3):809-20 - PubMed
  12. J Hepatol. 2004 Nov;41(5):864-80 - PubMed
  13. World J Hepatol. 2015 Mar 27;7(3):377-91 - PubMed
  14. World J Gastroenterol. 2014 Jul 21;20(27):9026-37 - PubMed
  15. Cytokine. 2012 Aug;59(2):442-9 - PubMed
  16. Hepatology. 2004 May;39(5):1185-95 - PubMed
  17. Am J Gastroenterol. 2003 Sep;98(9):2042-7 - PubMed
  18. Liver Int. 2011 Feb;31(2):146-62 - PubMed
  19. Clin Liver Dis. 2007 Feb;11(1):75-104, ix - PubMed
  20. Hepatology. 2005 Jun;41(6):1313-21 - PubMed
  21. J Hepatol. 2005 Jan;42(1):7-11 - PubMed
  22. World J Gastroenterol. 2009 Nov 7;15(41):5193-9 - PubMed
  23. JAMA. 2001 May 16;285(19):2486-97 - PubMed
  24. J Hepatol. 2011 Jun;54(6):1224-9 - PubMed
  25. Am J Surg Pathol. 2011 Sep;35(9):1400-4 - PubMed
  26. World J Gastroenterol. 2012 Feb 28;18(8):727-35 - PubMed
  27. Hepatology. 1997 Jan;25(1):229-34 - PubMed
  28. Hepatol Int. 2013 Mar;7(1):233-40 - PubMed
  29. J Clin Gastroenterol. 2006 Mar;40 Suppl 1:S17-29 - PubMed
  30. Eur J Gastroenterol Hepatol. 2010 Jun;22(6):643-50 - PubMed
  31. Arch Med Res. 2011 Jan;42(1):38-43 - PubMed
  32. Hepatology. 2006 Oct;44(4):983-91 - PubMed
  33. Histopathology. 2006 Nov;49(5):450-65 - PubMed
  34. Semin Liver Dis. 2015 Aug;35(3):221-35 - PubMed
  35. World J Gastroenterol. 2008 Feb 14;14(6):831-44 - PubMed
  36. World J Gastroenterol. 2005 Feb 21;11(7):960-3 - PubMed
  37. Ann Hepatol. 2009;8 Suppl 1:S4-8 - PubMed
  38. Proc Natl Acad Sci U S A. 2012 Apr 10;109(15):5874-9 - PubMed
  39. Rev Esp Enferm Dig. 2008 Apr;100(4):212-8 - PubMed
  40. Liver Int. 2014 Apr;34(4):521-34 - PubMed
  41. Hepatol Res. 2013 Nov;43(11):1241-50 - PubMed
  42. Eur J Gastroenterol Hepatol. 2009 May;21(5):504-11 - PubMed
  43. Gastroenterology. 2005 Jun;128(7):1898-906 - PubMed

Publication Types